Myomo (MYO) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Myomo (NYSEAMERICAN:MYO) from a sell rating to a hold rating in a research note released on Thursday.

According to Zacks, “Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro(R) product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals. Myomo, Inc. is headquartered in Cambridge,Massachusetts. “

Other analysts have also recently issued reports about the company. Roth Capital set a $7.00 price objective on Myomo and gave the company a buy rating in a research report on Thursday, May 10th. HC Wainwright set a $12.00 price target on Myomo and gave the stock a buy rating in a research report on Thursday, May 10th.

Myomo opened at $2.96 on Thursday, MarketBeat Ratings reports. Myomo has a fifty-two week low of $2.07 and a fifty-two week high of $13.50.

Myomo (NYSEAMERICAN:MYO) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.56 million. Myomo had a negative net margin of 257.70% and a negative return on equity of 155.42%.

Institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in shares of Myomo in the 4th quarter worth approximately $124,000. Citadel Advisors LLC boosted its position in shares of Myomo by 243.9% in the 1st quarter. Citadel Advisors LLC now owns 40,861 shares of the company’s stock worth $121,000 after purchasing an additional 28,981 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Myomo in the 4th quarter worth approximately $257,000. Hudson Bay Capital Management LP bought a new stake in shares of Myomo in the 4th quarter worth approximately $294,000. Finally, A.R.T. Advisors LLC purchased a new position in Myomo in the 1st quarter worth approximately $277,000.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Insider Selling: Commerce Bancshares, Inc.  Insider Sells 8,000 Shares of Stock
Insider Selling: Commerce Bancshares, Inc. Insider Sells 8,000 Shares of Stock
Associates L.L.C. Cdk Acquires 11,200 Shares of Strongbridge Biopharma plc  Stock
Associates L.L.C. Cdk Acquires 11,200 Shares of Strongbridge Biopharma plc Stock
$0.59 Earnings Per Share Expected for Southside Bancshares, Inc.  This Quarter
$0.59 Earnings Per Share Expected for Southside Bancshares, Inc. This Quarter
Inogen  Reaches New 12-Month High at $214.99
Inogen Reaches New 12-Month High at $214.99
Citrix Systems  Sets New 12-Month High at $110.94
Citrix Systems Sets New 12-Month High at $110.94
Insights Network Price Reaches $0.0202 on Top Exchanges
Insights Network Price Reaches $0.0202 on Top Exchanges


© 2006-2018 Ticker Report. Google+.